C
Claudio Doglioni
Researcher at Vita-Salute San Raffaele University
Publications - 556
Citations - 35063
Claudio Doglioni is an academic researcher from Vita-Salute San Raffaele University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 90, co-authored 504 publications receiving 31200 citations. Previous affiliations of Claudio Doglioni include Semmelweis University & University of Milan.
Papers
More filters
Journal ArticleDOI
Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori
Andrew Wotherspoon,Timothy C. Diss,Langxing Pan,Peter G. Isaacson,Claudio Doglioni,A. Moschini,M. de Boni +6 more
TL;DR: It is suggested that eradication of H pylori causes regression of low-grade B-cell gastric MALT lymphoma, and that anti-H-pylori treatment should be given for this lymphoma.
Journal ArticleDOI
Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
Federico Cappuzzo,Fred R. Hirsch,Elisa Rossi,Stefania Bartolini,Giovanni Luca Ceresoli,Lynne T. Bemis,Jerry Haney,Samir E. Witta,Kathleen D. Danenberg,I. Domenichini,Vienna Ludovini,Elisabetta Magrini,Vanesa Gregorc,Claudio Doglioni,Angelo Sidoni,Maurizio Tonato,Wilbur A. Franklin,Lucio Crinò,Paul A. Bunn,Marileila Varella-Garcia +19 more
TL;DR: High EGFR gene copy number identified by FISH may be an effective molecular predictor for gefitinib efficacy in advanced NSCLC and independent of EGFR assessment method, EGFR+/P-Akt+ patients had a statistically significantly better outcome than EGFR-, P- akt-, or EGFR-/Akt- patients.
Journal ArticleDOI
Pancreatic cancers require autophagy for tumor growth
Shenghong Yang,Xiaoxu Wang,Gianmarco Contino,Marc Liesa,Ergun Sahin,Haoqiang Ying,Alexandra S. Bause,Ying-Hua Li,Jayne M. Stommel,Giacomo Dell'Antonio,Josef Mautner,Giovanni Tonon,Marcia C. Haigis,Orian S. Shirihai,Claudio Doglioni,Nabeel Bardeesy,Alec C. Kimmelman +16 more
TL;DR: Inhibition of autophagy by genetic means or chloroquine treatment leads to robust tumor regression and prolonged survival in pancreatic cancer xenografts and genetic mouse models, and drugs that inactivate this process may have a unique clinical utility in treating pancreatic cancers and other malignancies with a similar dependence on Autophagy.
Journal ArticleDOI
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Margherita Norelli,Barbara Camisa,Giulia Barbiera,Laura Falcone,Ayurzana Purevdorj,Marco Genua,Francesca Sanvito,Maurilio Ponzoni,Claudio Doglioni,Patrizia Cristofori,Catia Traversari,Claudio Bordignon,Claudio Bordignon,Fabio Ciceri,Renato Ostuni,Chiara Bonini,Monica Casucci,Attilio Bondanza +17 more
TL;DR: A mouse model recapitulating key features of CRS and neurotoxicity is described, offering a therapeutic strategy to tackle neurotoxicity and open new avenues to safer CAR T cell therapies.
Journal ArticleDOI
Induction of EMT by Twist Proteins as a Collateral Effect of Tumor-Promoting Inactivation of Premature Senescence
Stéphane Ansieau,Jérémy Bastid,Jérémy Bastid,Agnès Doreau,Anne Pierre Morel,Benjamin Pierre Bouchet,Benjamin Pierre Bouchet,Clémence Thomas,Clémence Thomas,Frédérique Fauvet,Isabelle Puisieux,Claudio Doglioni,Sara Piccinin,Roberta Maestro,Thibault Voeltzel,Abdelkader Selmi,Abdelkader Selmi,Sandrine Valsesia-Wittmann,Claude Caron de Fromentel,Alain Puisieux,Alain Puisieux +20 more
TL;DR: It is shown that a large fraction of human cancers overexpress Twist1 and/or Twist2, suggesting an unanticipated direct link between early escape from failsafe programs and the acquisition of invasive features by cancer cells.